<DOC>
	<DOCNO>NCT01195831</DOCNO>
	<brief_summary>The purpose study compare clinical efficacy daily treatment 4 week Xamiol® gel ( calcipotriol plus betamethasone ) twice daily treatment 4 week Calcipotriol Scalp Solution patient scalp psoriasis .</brief_summary>
	<brief_title>Efficacy Safety Xamiol® Gel Compared Calcipotriol Scalp Solution Patients With Scalp Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Patients either gender 18 65 year age . A clinical diagnosis scalp psoriasis : investigator 's assessment clinical sign scalp least ≥ 2 one clinical sign , redness , thickness scaliness , least 1 two clinical sign , total score ≥ 4 , extent 10 % total scalp area , least moderate severity accord investigator 's global assessment . Clinical sign psoriasis vulgaris trunk and/or limb , early diagnose psoriasis vulgaris trunk and/or limb . The patient must provide sign date informed consent study related activity carry . Current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis . Patients follow condition present scalp area : viral lesion , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , acne vilgaris , acne rosacea , atrophic skin , stria atrophicae , fragility skin vein , ichthyosis , ulcer wound . Any inflammatory skin disease may confound evaluation scalp psoriasis Systemic treatment biological therapy ( market market ) , possible effect scalp psoriasis ( e.g. , alefacept , efalizumab , etanercept , infliximab ) within 3 month prior visit 1 study . Systemic treatment therapy biologicals , possible effect scalp psoriasis ( e.g. , corticosteroid , vitamin D analogue , retinoids , immunosuppressant ) within 4 week prior SV2 study . PUVA therapy within 4 week prior randomisation ( visit 1 ) study . UVB therapy wthin 2 week prior randomisation ( visit 1 ) study . Therapies within 2 week prior SV2 study . Topical treatment psoriasis non scalp psoriasis lesion potent potent ( WHO group IIIIV ) corticosteroid , Topical treatment Immunomodulator , e.g . Tacrolimus , Vitamin D analogue ( e.g , calcipotriol , tacalcitol , calcitriol ) , Any topical treatment scalp ( except nonsteroid medicate shampoo emollient , Other type psoriasis treatment , e.g . Chinese medicine , process Chinese medicine , hot spring , etc . Planned initiation , change concomitant medication could affect scalp psoriasis ( e.g. , beta blocker , antimalaria drug , lithium ) study . Known suspect hypersensitivity component ( ) Investigational Products . Known suspect abnormality calcium homeostasis . Known suspect severe renal insufficiency severe hepatic disorder , severe heart disease . Clinical sign symptoms Cushing 's disease Addison 's disease . Planned extensive exposure sun ( e.g . work outdoors ) study , may affect scalp psoriasis . Females pregnant , childbearing potential wish become pregnant study , breastfeed . Females childbearing potential positive serum urine pregnancy test SV2 . Any clinically significant abnormality follow review screen laboratory test ( blood urine sample ) , physical examination blood pressure/heart rate measurement perform SV2 . Participation interventional clinical trial within 4 week prior randomisation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>